AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05321654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for Behavior Modification
Description: Please see arm description for a detailed description of the intervention
Study NCT05321654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Program
Description: Please see arm description for a detailed description of the intervention
Study NCT05398991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.
Description: the Coronary Covered Stents System contains a covered stent and a delivery system
Study NCT05225194 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: SARS-CoV-2 infection
Study NCT05225194 — intervention group
Intervention type: OTHER
Intervention: ARDS
Description: Acute respiratory distress syndrome
Study NCT05338801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol-flavored e-cigarette
Description: All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
Study NCT05338801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-flavored e-cigarette
Description: All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
Study NCT05439590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High dose CSO
Description: Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
Study NCT05583812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation
Description: FB2001 once or twice daily inhalation
Study NCT05439590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose CSO
Description: Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
Study NCT05439590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose OO
Description: Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
Study NCT05439590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose OO
Description: Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
Study NCT05344781 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire regarding relationship and sexual satisfaction
Study NCT06472830 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT05583812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001 for inhalation placebo
Description: FB2001 placebo once or twice daily inhalation
Study NCT05977036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum® TKa assay
Description: Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
Study NCT05977036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 + Endocrine therapy
Description: FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
Study NCT05094557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual
Description: The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
Study NCT05102175 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Eligible participants will be invited to a semi-structured focus group discussion. Each group will include 8 -12 participants.
Study NCT05275400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC
Study NCT05275400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT05094557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual
Description: Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.
Study NCT05094557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Psychoeducational video + Treatment As usual
Description: Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
Study NCT05987202 — intervention group
Intervention type: OTHER
Intervention: DA closure in a population of premature infants
Description: Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
Study NCT04720248 — intervention group
Intervention type: DRUG
Intervention: Metamizole
Description: Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
Study NCT04876872 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05693701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Strategy Bundle
Description: Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
Study NCT05693701 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care notification
Description: Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
Study NCT05693701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care notification
Description: Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
Study NCT04796012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Feasibility and RMS Cohorts: Administered at 15 mg/kg (max 1,200 mg) IV on Day 1 of each 21-day cycle
Study NCT04796012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Feasibility and RMS Cohorts: Administered at 1.5 mg/m\^2 (max 2 mg) IV on Day 1 of each 21-day cycle
Study NCT04796012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Feasibility and RMS Cohorts: Administered at 50 mg/m2 IV on Days 1-5 of each 21-day cycle
Study NCT04796012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Feasibility and RMS Cohorts: Administered at 100 mg/m\^2 (max 200 mg) IV or PO 1 hour before irinotecan injection on Days 1-5 if each 21-day cycle
Study NCT05860634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter self-discontinuation
Description: Self-discontinuation of a transurethral catheter
Study NCT06598449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenfluramine
Description: Clear, cherry flavored oral solution
Study NCT06665256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapcabtagene autoleucel
Description: Single infusion of rapcabtagene autoleucel
Study NCT06665256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Option
Description: Investigator choice of treatment as per protocol
Study NCT06611254 — intervention group
Intervention type: DEVICE
Intervention: Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM
Description: CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
Study NCT06610877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound Neuromodulation
Description: Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
Study NCT06610877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound neuromodulation
Description: Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
Study NCT06403709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
Description: These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
Study NCT06610487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT1
Description: Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.
Study NCT06610487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT06609980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous fecal matter transplant
Description: Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
Study NCT06609421 — intervention group
Intervention type: OTHER
Intervention: Informative Appointment
Description: The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.
Study NCT06728163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written education group
Description: group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.
Study NCT06728163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational material + breathing relaxation with verbal instruction
Description: group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. Verbal instructions for breathing are provided for about 3 minutes and 3 seconds.
Study NCT06728163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR educational material + breathing relaxation with music intervention
Description: group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
Study NCT06728163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written educational material + breathing relaxation with music intervention.
Description: group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.~The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
Study NCT06728722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of body composition
Description: Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length.
Study NCT06728852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Vorolanib
Description: This study utilizes Vorolanib, a novel angiogenesis inhibitor, as a monotherapy for advanced non-small cell lung cancer (NSCLC) patients who have failed at least two lines of systemic therapy. Vorolanib is administered orally at a dosage of 300 mg daily. The intervention focuses on its efficacy and safety as a third-line or beyond treatment, aiming to improve progression-free survival (PFS) and other clinical outcomes. Vorolanib targets VEGFR, PDGFR, and other tyrosine kinases, distinguishing it from other therapies by its enhanced anti-angiogenesis properties and tolerable safety profile in late-stage cancer treatment.
Study NCT06729788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON resin infiltration Material group in vivo
Description: The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK).
Study NCT06729788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resin-based fissure sealant group in vivo
Description: The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)
Study NCT06729788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON resin infiltration in vitro
Description: The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK) in vitro
Study NCT06729788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resin-based fissure sealant in vitro
Description: The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael) in vitro
Study NCT05366426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMG biofeedback program:
Description: Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
Study NCT05366426 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham EMG biofeededback:
Description: 3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
Study NCT05366426 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
Study NCT05366426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
Study NCT05366426 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor muscle training home exercise program:
Description: Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
Study NCT05717439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5-R
Description: A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
Study NCT05717439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Senseye DT
Description: Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
Study NCT04698434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: each group was given a single intravenous dose of the corresponding esketamine.
Study NCT06551753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality app
Description: virtual reality app
Study NCT05338463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fespixon Cream
Description: 1. Name : Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 20 weeks
Study NCT05033132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
Study NCT05033132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab + Zalifrelimab
Description: An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody